Posted by Michael Wonder on 10 May 2024
Qulipta (atogepant) now approved by Health Canada for the preventive treatment of chronic migraine in adults
8 May 2024 - Approval was based on a pivotal Phase 3 clinical trial that demonstrated statistically significant reduction from baseline in mean monthly migraine days.
AbbVie announced today that Health Canada has approved Qulipta (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.
